Shanghai Henlius Biotech Reports the First Patient Dosing of HLX15 (biosimilar, daratumumab) in P-I Clinical Trial for Multiple Myeloma
Shots:
- The first patient has been dosed in the P-I trial that consists of 2 parts (parts 1 & 2) evaluating HLX15 (anti-CD38 IgG1κ mAb) vs daratumumab in 234 patients with MM
- Part 1 is an open-label, two-arm P-Ia study & part 2 is a three-arm P-Ib study evaluating HLX15 (8mg/kg) vs China & US-sourced daratumumab in a ratio (1:1) & (1:1:1) in 24 & 204 patients while part 2 is a three-arm P-Ib study. The early phase of part 1 includes a safety run-in period with 3-6 patients to receive HLX15 (IV), monitored for safety for 1wk.
- The 1EP is the area under the serum drug concentration-time curve from time 0 to infinity & 2EPs incl. other PK parameters, safety & immunogenicity. In preclinical studies, HLX15 is highly similar to daratumumab
Ref: Henlius | Image: Henlius
Related News:- Henlius' HLX15 (biosimilar- daratumumab) Receives IND Approval for Multiple Myeloma in China
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
